-
384O Laparoscopic versus open hemihepatectomy: The ORANGE II PLUS multicenter randomized controlled trial2021 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Robert S. Fichtinger, Luca Antonio Aldrighetti, Roberto Ivan TROISI, Mohammad Abu Hilal, Robert Peter Sutcliffe, Marc G. Besselink, +14 more
9citations -
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)2022 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
A. Vogel, S. Boeck, O. Waidmann, Michael Bitzer, P. Wenzel, S. Belle, +13 more
9citations -
1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)2021 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Hans A. J. Gelderblom, Albiruni Ryan Abdul Razak, Amparo Sánchez-Gastaldo, Piotr Lukasz Rutkowski, Breelyn Ann Wilky, Michiel A. J. van de Sande, +5 more
8citations -
LBA74 Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 12025 Annals of Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
Sanjay Popat, Norio Yamamoto, Nicolas M Girard, Yi-Long Lung Cancer Wu, Gerrina Ruiter, Egbert Frederik Smit, +8 more
8citations -
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study
Matthijs van der Meulen, Katerina Bakunina, Marcel Nijland, Monique C. Minnema, Gavin Cull, Wendy B.C. Stevens, +10 more
7citations -
LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 7432022 Annals of Oncology conference-abstract Medicine Occupational and environmental lung diseases Open access
Gérard Zalcman, Y. Oulkhouir, Robin Cornelissen, Laurent Greillier, Jerónimo Rodríguez Cid, Julien Mazières, +12 more
7citations -
Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial2026 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro Peccatori, Hatem A. Azim, Marco Angelo Colleoni, +33 more
7citations -
1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Sapna Pradyuman Patel, Meredith Ann McKean, S. Piperno-Neumann, Alexander Noor Shoushtari, Leonel Fernando Hernandez-Aya, Marlana M. Orloff, +11 more
6citations -
138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
JMS Bartlett, Keying Xu, Gregory R. Pond, Yi Zhang, Melanie Spears, Ranelle C. Salunga, +11 more
5citations -
601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours2020 Annals of Oncology article Medicine Cancer-related Molecular Pathways Open access cited by 2 patents
Hans A. J. Gelderblom, Jourik A. Gietema, Ingrid M.E. Desar, N.M. Ajmone, Mathilde Jalving, Judith R. Kroep, +5 more
5citations -
1509P Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion2022 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Jean‐Yves Blay, H. Gelderblom, P. Rutkowski, A. Wagner, Meike van de Sande, A. Falcon Gonzalez, +13 more
5citations -
133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
V.C.G. Tjan-Heijnen, S.W.M. Lammers, Sandra M. E. Geurts, Ingeborg J. H. Vriens, Astrid C P Swinkels, Carolien H. Smorenburg, +8 more
5citations -
1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)2022 Annals of Oncology article Immunology and Microbiology Immunotherapy and Immune Responses Open access
J.F. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, +14 more
5citations -
LBA59 Combined percutaneous hepatic perfusion with ipilimumab plus nivolumab in metastatic uveal melanoma (CHOPIN): A single-center, open-label, randomized, phase II study
E. Kapiteijn, Frank M. Speetjens, Stephanie M. Zunder, Arian R. van Erkel, Carla van Rijswijk, Jacob Lutjeboer, +11 more
5citations -
LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial2025 Annals of Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
O. Pagani, Samuel M. Niman, Fedro Alessandro Peccatori, Hatem A. Azim, M.A. Colleoni, Cristina Saura, +10 more
5citations -
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial2021 Annals of Oncology article Biochemistry, Genetics and Molecular Biology BRCA gene mutations in cancer Open access
Alba Llop‐Guevara, Valentina A. Vladimirova, Andreas Schneeweiß, Guillermo Javierre Villacampa, Thomas Karn, D-M. Zahm, +14 more
4citations -
1623MO Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Filip Jankú, Ping Chi, Michael Charles Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, +9 more
4citations -
476P First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors2022 Annals of Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
F. A. L. M. Eskens, F. Opdam, E. Gort, H. Gelderblom, L. Prestegarden, C. Pico-Navarro
4citations -
878P Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Anthony H. Kong, Caroline Even, Begoña Aguilera, Marielle Klein Hesselink, Sonja Visscher, J.C. Park, +9 more
4citations -
1260TiP The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction (TRAP-2)
D. Blangé, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Bianca Mostert, Marije Slingerland, N. Haj Mohammad, +14 more
4citations